Abstract
In this study, we have evaluated the clinical value of the high-sensitivity C-reactive protein (hs-CRP) level in predicting the risk of coronary artery disease (CAD) in hyperglycemic subjects of Bangladesh. A total of 201 participants were selected for this study and fasting venous blood samples are collected from them for measuring fasting plasma glucose (FPG), serum total cholesterol (TC), triglycerides (TG), LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C), hs-CRP, apolipoprotein A-1, apolipoprotein B and lipoprotein(a). CAD risk of study subjects was estimated with the use of Framingham Risk Score (FRS). Out of 201, 91 study participants are found as normal fasting glucose (NFG), 56 as impaired fasting glucose (IFG) and 54 as diabetes mellitus. The average levels of TC, TG, LDL-C, HDL-C, TC/HDL-C ratio, apolipoprotein A-1, apolipoprotein B and lipoprotein(a) in NFG, IFG and diabetes are not significantly different between each group. Statistically significant (p < 0.001) differences are observed between each group of hs-CRP levels. Among the components of FRS; age, systolic blood pressure and HDL-C are significantly correlated with an increase in concentration of FPG. The estimated Framingham 10-year risk of CAD and hs-CRP levels are significantly increasing with the concentration of FPG. Before and after adjusting for covariates (age, sex, smoking status, TC and HDL-C), it is found that FPG is significantly associated with hs-CRP level. Interestingly, serum hs-CRP levels are significantly increased in the higher FPG groups before and after adjustment by covariates. Finally, this study demonstrates hs-CRP as a stronger predictor of cardiovascular events in hyperglycemic subjects thereby helping to assess the risk of CAD induced by hyperglycemia.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Diabetes Association (2006) Diagnosis and classification of diabetes mellitus. Diabetes Care, 29(Suppl 1), S43–48.
Anderson, K. M., Odell, P. M., Wilson, P. W., & Kannel, W. B. (1991). Cardiovascular disease risk profiles. American Heart Journal, 121, 293–298.
Brindle, P., Beswick, A., Fahey, T., & Ebrahim, S. (2006). Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: A systematic review. Heart, 92, 1752–1759.
Castell, J. V., Gómez-Lechón, M. J., David, M., Fabra, R., Trullenque, R., & Heinrich, P. C. (1990). Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology, 12, 1179–1186.
Committee and on the Diagnosis and Classification of Diabetes Mellitus, 2003 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care, 26, 3160–3167.
Danesh, J., Whincup, P., Walker, M., Lucy, L., Andrew, T., Paul, A., Gallimore, J. R., & Mark, B. P. (2000). Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. British Medical J, 321, 199–204.
Devaraj, S., Xu, D. Y., & Jialal, I. (2003). C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: Implications for the metabolic syndrome and atherothrombosis. Circulation, 107, 398–404.
Expert Panel on Detection and Evaluation, and Treatment of High Blood Cholesterol in Adults 2001 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 285, 2486-2897.
Fornengo, P., Bosio, A., Epifani, G., Pallisco, O., Mancuso, A., & Pascale, C. (2006). Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. Diabetic Medicine, 23, 775–779.
Hayaishi-Okano, R., Yamasaki, Y., Katakami, N., Ohtoshi, K., Goragawa, S. I., Kuroda, A., Matsuhisa, M., Kosugi, K., Nishikawa, N., Kajimoto, Y., & Hori, M. (2002). Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care, 25, 1432–1438.
Hossain, E., Islam, K., Yeasmin, F., Karim, M. R., Rahman, M., Agarwal, S., Hossain, S., Aziz, A., Mamun, A. A., Sheikh, A., Haque, A., Hossain, M. T., Hossain, M., Haris, P. I., Ikemura, N., Inoue, K., Miyataka, H., Himeno, S., & Hossain, K. (2012). Elevated levels of plasma Big endothelin-1 and its relation to hypertension and skin lesions in individuals exposed to arsenic. Toxicology and Applied Pharmacology, 259, 187–194.
Kharlip, J., Naglieri, R., Mitchell, B. D., Ryan, K. A., & Donner, T. W. (2006). Screening for silent coronary heart disease in type 2 diabetes: Clinical application of American Diabetes Association guidelines. Diabetes Care, 29, 692–694.
Koenig, W., Löwel, H., Baumert, J., & Meisinger, C. (2004). C-reactive protein modulates risk prediction based on the Framingham score: Implications for future risk assessment: Results from a large cohort study in southern Germany. Circulation, 109, 1349–1353.
Laakso, M., & Kuusisto, J. (1996). Epidemiological evidence for the association of hyperglycaemia and atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Annals of Medicine, 28, 415–418.
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994). The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. New England Journal of Medicine, 331, 417–424.
Nathan, D. M. (1993). Long-term complications of diabetes mellitus. New England Journal of Medicine, 328, 1676–1685.
Ridker, P. M. (2001). High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation, 103, 1813–1818.
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New England Journal of Medicine, 342, 836–843.
Ross, R. (1999). Atherosclerosis—an inflammatory disease. New England Journal of Medicine, 340, 115–126.
Ruderman, N. B., Gupta, S., & Sussman, I. (1992). Hyperglycemia, diabetes, and vascular disease: An overview. In N. Ruderman, J. Williamson, & M. Brownlee (Eds.), Hyperglycemia, Diabetes, and Vascular Disease. Clinical Physiology Series (pp. 3–20). New York: Springer.
Sabatine, M. S., Morrow, D. A., Jablonski, K. A., Rice, M. M., Warnica, J. W., Domanski, M. J., Hsia, J., Gersh, B. J., Rifai, N., Ridker, P. M., Pfeffer, M. A., Braunwald, E., & Investigators, P. E. A. C. E. (2007). Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. Circulation, 115, 1528–1536.
Schulze, M. B., Rimm, E. B., Li, T., Rifai, N., Stampfer, M. J., & Hu, F. B. (2004). C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care, 27, 889–894.
Soinio, M., Marniemi, J., Laakso, M., Lehto, S., & Rönnemaa, T. (2006). High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: A 7-year follow-up study. Diabetes Care, 29, 329–333.
Steiner, G. (1985). Atherosclerosis, the major complications of diabetes. Advances in Experimental Medicine and Biology, 189, 277–297.
Verma, S., Wang, C. H., Li, S. H., Dumont, A. S., Fedak, P. W. M., Badiwala, M. V., Dhillon, B., Weisel, R. D., Li, R. K., Mickle, D. A. G., & Stewart, D. J. (2002). A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation, 106, 913–919.
Wilson, P. W., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97, 1837–1847.
Woodward, M., Brindle, P., & Tunstall-Pedoe, H. (2007). Adding social deprivation and family history to cardiovascular risk assessment: The ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart, 93, 172–176.
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., et al. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart study): Case-control study. Lancet, 364, 937–952.
Zellweger, M. J. (2006). Prognostic significance of silent coronary artery disease in type 2 diabetes. Herz, 31, 240–245.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Islam, M.S., Habib, R., Karim, M.R., Yeasmin, T. (2021). Role of Serum High-Sensitivity C-Reactive Protein Level as Risk Factor in the Prediction of Coronary Artery Disease in Hyperglycemic Subjects. In: Sinha, B.K., Mollah, M.N.H. (eds) Data Science and SDGs. Springer, Singapore. https://doi.org/10.1007/978-981-16-1919-9_10
Download citation
DOI: https://doi.org/10.1007/978-981-16-1919-9_10
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-16-1918-2
Online ISBN: 978-981-16-1919-9
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)